Insights

Strategic Opportunity Potential partnership with Pfizer for ongoing ACCURINS development and commercialization support given historical asset alignment and continued collaboration.

Targeted Oncology Focus on cancer nanotechnology delivery systems suggests sales opportunities with oncology-focused CROs, academic cancer centers, and pharma seeking advanced targeted therapies.

Financing Signals Modest revenue and early-stage funding indicate a need for strategic collaborations, milestone-driven deals, and co-development agreements to de-risk investments.

Acquisition Footprint Historical asset transfer to Pfizer implies evaluating legacy ACCURINS program assets for buyout, licensing, or sublicense arrangements with large biotech players.

Industry Alignment Past high-profile partnerships (AstraZeneca in past, Pfizer ongoing) show receptivity to external partnerships; target biopharma companies investing in nanoparticle-based delivery and precision medicine.

BIND Therapeutics's Email Address Formats

BIND Therapeutics uses at least 1 format(s):

BIND Therapeutics Email Formats	Example	Percentage
FLast@bindtherapeutics.com	JDoe@bindtherapeutics.com	29%
Last@bindtherapeutics.com	Doe@bindtherapeutics.com	28%
FirstLast@bindtherapeutics.com	JohnDoe@bindtherapeutics.com	29%
First.Last@bindtherapeutics.com	John.Doe@bindtherapeutics.com	14%

BIND Therapeutics Email Formats

Example

Percentage

FLast@bindtherapeutics.com

JDoe@bindtherapeutics.com

29%

Last@bindtherapeutics.com

Doe@bindtherapeutics.com

28%

FirstLast@bindtherapeutics.com

JohnDoe@bindtherapeutics.com

29%

First.Last@bindtherapeutics.com

John.Doe@bindtherapeutics.com

14%

Frequently Asked Questions

What is BIND Therapeutics's phone number?

You can contact BIND Therapeutics's main corporate office by phone at

+1-617-491-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is BIND Therapeutics's official website and social media links?

BIND Therapeutics's official website is bindtherapeutics.com and has social profiles on LinkedIn Crunchbase.

How much revenue does BIND Therapeutics generate?

As of July 2026, BIND Therapeutics's annual revenue is estimated to be $1M - $10M.

What is BIND Therapeutics's SIC code NAICS code?

BIND Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BIND Therapeutics have currently?

As of July 2026, BIND Therapeutics has approximately 4 employees across 2 continents, including North AmericaAsia. Key team members include Chief Technology Officer: J. H.Director, New Product Planning: A. M.. Explore BIND Therapeutics's employee directory with LeadIQ.

What industry does BIND Therapeutics belong to?

BIND Therapeutics operates in the Biotechnology Research industry.

What is BIND Therapeutics's email format?

BIND Therapeutics's email format typically follows the pattern of FLast@bindtherapeutics.com. Find more BIND Therapeutics email formats with LeadIQ.

How much funding has BIND Therapeutics raised to date?

As of July 2026, BIND Therapeutics has raised $92M in funding. The last funding round occurred on Feb 05, 2015 for $22M.

When was BIND Therapeutics founded?

BIND Therapeutics was founded in 2006.

BIND Therapeutics

Q: How many employees does BIND Therapeutics have currently?

BIND Therapeutics has approximately 4 employees.

Q: What is BIND Therapeutics's NAICS code?

BIND Therapeutics's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchMassachusetts, United States2-10 Employees

BIND Therapeutics is a biotechnology company founded in 2006 and based in Cambridge, Massachusetts. Its work centers on developing targeted drug delivery systems designed to direct therapeutic agents to specific cells and tissues involved in disease, aiming to enable treatment approaches not achievable with conventional methods. The company’s primary focus has been on ACCURINS, proprietary nanoparticles intended to enhance targeting and therapeutic outcomes, with ongoing development activity in collaboration with Pfizer.

The market for BIND’s work lies in oncology and other areas where precise delivery can improve treatment effectiveness. Its location in the Cambridge biopharma ecosystem places it among a concentration of research-focused firms pursuing advanced delivery technologies. Recent developments include collaborations with Pfizer related to the continued development of ACCURINS, reflecting ongoing partnerships within the pharmaceutical industry.

Insights

Similar companies to BIND Therapeutics

Selecta Biosciences

Starpharma

Ipsen

Enzon Pharmaceuticals

Media & News

Pfizer Inc partners with Bindtherapeutics.